Skip to main content
Premium Trial:

Request an Annual Quote

Sankyo Pharma Taps Gentris for Pharmacogenomics Diagnostics

NEW YORK, Feb. 24 - Gentris, a North Carolina clinical pharmacogenomics company, said today that it has begun a three-year non-exclusive collaboration with Sankyo Pharma, the US subsidiary of Japanese pharmaceutical firm Sankyo Co., Ltd.

 

The companies will partner on a pharmacogenomic test panel based on proprietary tests developed by Gentris to investigate drug pharmacokinetics, pharmacodynamics, safety, and efficacy.  

 

In addition, Gentris and Sankyo Pharma said they would work jointly on new diagnostic tests to complement Sankyo's new drugs.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.